Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Research & Development: €0.0 Mil (TTM As of Mar. 2026)


XMAD:ROVI Laboratorios Farmaceuticos Rovi SA XMAD:ROVI
100 GF Score
Price €58.60
GF Value €50.93
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Research & Development?

Laboratorios Farmaceuticos Rovi XMAD:ROVI -1.10% 100 Research & Development is €0.0 Mil as of Mar. 2026. GuruFocus rates XMAD:ROVI with a GF Score™ of 100/100 and a GF Value™ of €50.93 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Laboratorios Farmaceuticos Rovi's Research & Development for the three months ended in Mar. 2026 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Laboratorios Farmaceuticos Rovi Research & Development Related Terms

Laboratorios Farmaceuticos Rovi Research & Development Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Research & Development Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XMAD:ROVI
100GF Score
Laboratorios Farmaceuticos Rovi SA XMAD:ROVI
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a Research & Development of €0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Research & Development too high?
Laboratorios Farmaceuticos Rovi's current Research & Development is €0.0 Mil. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 100/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Research & Development compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Research & Development of €0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.93, compared to a current price of €58.60 — trading 15.1% above its estimated fair value. The current Research & Development is €0.0 Mil. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current Research & Development is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of €58.60 is trading 15.1% above its estimated GF Value™ of €50.93. GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.

Key valuation signals for XMAD:ROVI:

  • Research & Development: €0.0 Mil
  • GF Value™: €50.93 vs. price of €58.60 (15.1% above fair value)
  • GF Score™: 100/100 with 1 warning sign

No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
100GF Score

Get the complete analysis for XMAD:ROVI

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.60
Price
€50.93
GF Value